Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Cells

Rita Leporati¹  Claudio Vernieri¹  Giancarlo Pruneri¹  Andrea Vingiani¹  Riccardo Lobefaro¹  Francesca Ligorio¹  Emma Zattarin¹ 

[1] Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133 Milan, Italy;

关键词: breast cancer;    hormone receptors;    conversion;    intratumor heterogeneity;    clonal selection;    endocrine therapies;   

DOI  :  10.3390/cells9122644

来源: DOAJ

【 摘 要 】

Hormone receptor-positive breast cancer (HR+ BC) accounts for approximately 75% of new BC diagnoses. Despite the undisputable progresses obtained in the treatment of HR+ BC in recent years, primary or acquired resistance to endocrine therapies still represents a clinically relevant issue, and is largely responsible for disease recurrence after curative surgery, as well as for disease progression in the metastatic setting. Among the mechanisms causing primary or acquired resistance to endocrine therapies is the loss of estrogen/progesterone receptor expression, which could make BC cells independent of estrogen stimulation and, consequently, resistant to estrogen deprivation or the pharmacological inhibition of estrogen receptors. This review aims at discussing the molecular mechanisms and the clinical implications of HR loss as a result of the therapies used in the neoadjuvant setting or for the treatment of advanced disease in HR+ BC patients.

【 授权许可】

Unknown